Posted by Michael Wonder on 21 Oct 2015
Tris Pharma receives FDA approval of Dyanavel XR (amphetamine) CII as once-daily liquid for treatment of ADHD in children
20 October 2015 - Tris Pharma, Inc. announced that the U.S. Food and Drug Administration has approved Dyanavel XR (amphetamine), extended-release oral suspension, CII, for the treatment of attention deficit hyperactivity disorder in children 6 years and older.
For more details, go to: http://www.trispharma.com/news_dyan2015.php
